当前位置：
X-MOL 学术
›
Nat. Rev. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Kidney cancer: First-in-class HIF2α antagonist safe and effective
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2018-01-16 , DOI: 10.1038/nrclinonc.2018.3 Peter Sidaway
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2018-01-16 , DOI: 10.1038/nrclinonc.2018.3 Peter Sidaway
Kidney cancer: First-in-class HIF2α antagonist safe and effective
中文翻译：
肾脏癌：一流的HIF2α拮抗剂安全有效
肾脏癌：一流的HIF2α拮抗剂安全有效
更新日期：2018-01-16
Kidney cancer: First-in-class HIF2α antagonist safe and effective, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.3
Kidney cancer: First-in-class HIF2α antagonist safe and effective中文翻译：
肾脏癌：一流的HIF2α拮抗剂安全有效
肾脏癌：一流的HIF2α拮抗剂安全有效
肾癌：安全有效的一流HIF2α拮抗剂，在线发布：2018年1月16日; doi：10.1038 / nrclinonc.2018.3
肾脏癌：一流的HIF2α拮抗剂安全有效
京公网安备 11010802027423号